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Abstract
The aim of this study was to evaluate glucose-bearing niosomes as a brain targeted delivery system for the vasoactive intestinal
peptide (VIP).
To this end, VIP/125I-VIP-loaded glucose-bearing niosomes were intravenously injected to mice. Brain uptake was determined
by measuring the radioactivity of 125I-labeled VIP using -counting, after intravenous administration of VIP in solution or
encapsulated in glucose-bearing niosomes or in control niosomes. VIP integrity was assessed by reversed-phase HPLC analysis
of brain extracts. Distribution of 125I-VIP derived radioactivity was examined from serial brain slices.
HPLC analysis confirmed the presence of intact VIP in brain after administration of VIP-loaded niosomes, but not after
administration of VIP solution. Encapsulation within glucose-bearing niosomes mainly allowed a significantly higher VIP brain
uptake compared to control niosomes (up to 86%, 5 min after treatment). Brain distribution of intact VIP after injection of
glucose-bearing niosomes, indicated that radioactivity was preferentially located in the posterior and the anterior parts of the
brain, whereas it was homogeneously distributed in the whole brain after the administration of control vesicles.
∗ Corresponding author. Tel.: +33 5 49 45 37 25; fax: +33 5 49 45 39 76.
E-mail address: Jean.Marc.Muller@univ-poitiers.fr (J.-M. Muller).
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In conclusion, this novel vesicular formulation of VIP delivers intact VIP to particular brain regions in mice. Glucose-bearing
vesicles might be therefore a novel tool to deliver drugs across the blood–brain barrier (BBB).
© 2004 Elsevier B.V. All rights reserved.
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1. Introduction
The vasoactive intestinal peptide (VIP) is a
28-amino acid neuropeptide of the glucagon-secretin
family (Mutt and Said, 1970) with a widespread distri-
bution in both the central and peripheral nervous system
(Fahrenkrug, 1979). It exerts diverse peripheral bio-
logical functions, such as anti-inflammatory and im-
munomodulatory effects, regulation of cell growth and
differentiation and participation in the development of
neural tissue (Muller et al., 1995). It also possesses
neuroprotective properties that influence the survival of
activity-dependent neurons in the central nervous sys-
tem, and plays an important role in cerebral metabolism
(Magistretti et al., 1981) and in cerebral carcinogene-
sis (Lelie`vre et al., 1998). VIP may have interesting
applications in the treatment of various neurological
disorders: a lipophilic VIP analogue was proposed as
a therapy against Alzheimer’s disease (Gozes et al.,
1996). However, like most endogenous peptides, its po-
tential therapeutic applications are limited by its failure
to cross the blood–brain barrier (BBB) which strictly
controls the access of solutes to the brain (Begley,
1996) and by its rapid elimination after intravenous
administration. Its blood half-life is less than 1 min in
rat (Hassan et al., 1994) and approximately 1 min in
man (Domschke et al., 1978). However, it has recently
been shown that a weak amount of VIP appeared to
reach the brain in conditions where a large amount
of intravenous radiolabelled peptide was administrated
(Dogrukol-Ak et al., 2003), which allowed to increase
the sensitivity of the brain delivery assays utilized in
these studies but also possible risks of side effects
of this high concentration of free circulating radio-
peptide.
In order to overcome this limitation, liposomal for-
mulations for intravenous use have been proposed to
protect VIP from degradation (Gao et al., 1994; Suzuki
et al., 1996; Se´journe´ et al., 1997; Gololobov et al.,
1998; ¨Onyu¨ksel et al., 1999). However, as liposomes
were unable to cross the BBB, the sole pharmacolog-
ical effect obtained was a peripheral vasodilation. We
recently delivered with success intact VIP to the brain
in rats, by using an intranasal route of administration
(Dufes et al., 2003). Through this pathway, VIP not
only circumvents the BBB, but the polypeptide also
avoids the hepatic first-pass effect and/or degradation
in the blood compartment, a particularly important is-
sue in the case of peptide drugs. Also for brain delivery,
a VIP analogue was conjugated to the OX26 mono-
clonal murine antibody directed against the rat trans-
ferrin receptor (Bickel et al., 1993). This conjugation
permitted a significant brain uptake of the analogue
administered intravenously in rats, associated with a
65% increase in cerebral blood flow, compared to basal
level (Bickel et al., 1993). Despite these attempts, no
procedure promoting the passage of inherently non-
penetrating drugs through the intact brain blood ves-
sel endothelium in their unmodified form is currently
available.
Glucose analogues are theoretically good candi-
dates for drug transport through the BBB. Indeed, the
large and uninterrupted energetic demand of the brain is
provided almost exclusively by -d-glucose. Further-
more, the glucose consumption of the brain amounts to
about 30% of the total body glucose consumption (Dick
et al., 1984; La Manna and Harik, 1985). This high level
of cerebral glucose uptake suggests that the facilita-
tive -d-glucose transporter GLUT1 might be a useful
carrier for efficient and selective glucose-targeted drug
delivery to the brain. Previous works using glucose-
chlorambucil derivatives and glycopeptide enkephalin
analogues, as reported by Halmos et al. (1997) and
Polt et al. (1994), respectively, indicate indeed that
brain targeting through GLUT-1 mediated transport of
glucose derivatives is possible. We hypothesized that
VIP may reach the brain parenchyma in an intact form
after encapsulation in a glucose-targeted system. To
this end, we formulated VIP in glucose-targeted nio-
somes made from N-palmitoylglucosamine (Dufes et
al., 2000), compared to the plain VIP niosomes and to
the free drug.
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2. Materials and methods
2.1. Chemicals
N-Palmitoylglucosamine (NPG) (Dufes et al., 2000)
and 125I-VIP (Martin et al., 1986; Pineau et al., 2001)
were synthesized and characterized as previously de-
scribed. Human VIP was obtained from Neosystem
(France). Bovine serum albumin (BSA), trifluoroacetic
acid (TFA), sorbitan monostearate (Span 60) and
cholesterol were all purchased from Sigma (France).
Cholesteryl poly-24-oxyethylene ether (Solulan C24)
was obtained from Amerchol (USA).
2.2. Animals
Male Swiss mice (30–40 g) obtained from De´pre´s
Breeding Laboratories (St. Doulchard, France) were
housed in the animal breeding facilities of the labora-
tory (Authorization no. 0028) for 4–6 days before ex-
periments. They were maintained in a light-controlled
(12/12 h light–dark cycle) and temperature-controlled
environment with water and food ad libitum. Experi-
mental procedures adhered to the Principles of Labo-
ratory Animal Care (NIH Publication # 86-23, revised
1985).
2.3. Preparation of VIP loaded niosomes
N-Palmitoylglucosamine (NPG) niosomes entrap-
ping VIP were prepared by shaking a mixture of NPG
(16 mg), Span 60 (65 mg), cholesterol (58 mg), Solulan
C24 (54 mg) in PBS (0.1 M, pH = 7.4, 1.5 mL) at 90 ◦C
for 30 min, followed by probe sonication (Soniprep
150, Fisher Scientific) for 5 min with the instrument
set at 75% of its maximal capacity. The whole proce-
dure of heating and sonication was repeated once. VIP
was entrapped into niosomes by probe sonicating them
in 125I-VIP (5 × 106 cpm/mL final concentration) and
unlabelled VIP (10−9 mol/mL final concentration, pre-
pared in PBS or in PBS supplemented with 1% (w/v)
BSA), in order to reduce the adsorption of VIP onto
containers.
Control niosomes (without glucose) entrapping VIP
were prepared in the same manner from a mixture
of Span 60 (73 mg), cholesterol (65 mg), Solulan C24
(54 mg) in PBS (1.5 mL) or in PBS supplemented with
1% (w/v) BSA).
To separate unencapsulated VIP from encapsulated
VIP, the mixture was then centrifuged (150,000 ×
g, first for 1 h, then for 30 min, Optima LE-80K ul-
tracentrifuge, Beckman Instruments, France) and the
supernatant containing the unencapsulated VIP was
discarded. After each ultracentrifugation step, the pel-
leted vesicles were resuspended in PBS (2 mL).
2.4. Vesicle analysis
2.4.1. Assay for the amount of VIP entrapped by
the vesicles
Radioactivity in control or glucose-bearing vesicles
was counted using a Cobra II Auto-Gamma Counting
System (Packard, USA).
2.4.2. Vesicle sizing
Vesicle sizing was performed by photon correlation
spectroscopy on a Malvern Zetasizer (Malvern Instru-
ments, UK).
2.5. Uptake of VIP entrapped in glucose-bearing
vesicles in brain
Mice (n = 4 animals/group) received three intra-
venous injections, at 5 min intervals, of VIP/125I-VIP,
free or encapsulated in glucose-bearing vesicles or
in control vesicles. These formulations were admin-
istered at a dose equivalent to 6.6× 10−10 mol/kg VIP
(100,000 cpm 125I-VIP per 0.1 mL injection).
Five, 15 or 30 min after the last injection, the mice
were sacrificed by cervical dislocation and a blood sam-
ple was collected by intracardiac puncture. A 200 mL
volume of saline (0.9% w/v sodium chloride) was then
infused at room temperature into the clamped aorta to
remove blood from brain vessels carefully. The brain
was removed and weighed, and its radioactivity, as well
as the radioactivity of the blood sample, was deter-
mined by -counting.
2.6. HPLC analysis of intact VIP in the brain
In an additional experiment the VIP integrity was
examined by HPLC, after administration of VIP, free
or entrapped in control or glucose-bearing niosomes.
Mice were dosed as above and sacrificed 15 min
after the last administration. Brains were washed
as described above, homogenized on ice with two
80 C. Dufes et al. / International Journal of Pharmaceutics 285 (2004) 77–85
volumes of 10 mM Tris buffer (pH 8) containing
protease inhibitors (1 mg/mL bacitracin, 1 mM phenyl-
methylsulfonylfluoride, 0.2 mM antipaı¨ne and 2 mM
orthophenanthroline) using a Teflon-glass Potter tis-
sue homogenizer and centrifuged at 4 ◦C (1,000 × g
for 10 min). Supernatants were collected and stored on
ice. The homogenization and centrifugation steps were
applied two more times to the pellets. Finally, the three
supernatants collected for each sample were pooled and
ultracentrifuged at 100,000 × g for 30 min at 4 ◦C to
spin down any remaining tissue debris. The clear super-
natant layers were collected and dried under vacuum
using a Speed-Vac (Heto Maxi Dry Lyo FD1.0). Ex-
tracts were dissolved in 200L mobile phase prior to
HPLC analysis.
VIP reversed-phase HPLC was carried out using a
5m VYDAC C18 column (Interchrom, France) with
-counting of 125I-VIP. A two-step linear gradient was
used with 0.1% (v/v) TFA in water as solvent A and
85:15 acetonitrile: 0.1% (v/v) TFA in water as solvent
B. The column was equilibrated with solvent A at a
1 mL/min flow-rate. Injection volume was 100L. At
each run, solvent B increased linearly from 0 to 35% in
2 min, then up to 100% in further 15 min, and was main-
tained at 100% for another 5 min. Fractions of 1 mL
were collected and -counted. VIP eluted in fractions
13–15.
2.7. Intracerebral distribution of VIP after
administration in vesicles
VIP formulations were administered as described
above. Mice were anesthetized by intraperitoneal in-
jection of 0.6% (w/v) chloral hydrate (300 mg/kg body
weight) and perfused through the heart with 100 mL
physiological saline followed by 200 mL fixative (4%
w/v paraformaldehyde in saline). Brains were removed
and cut serially (2.5 mm-thick slices). Radioactivity
was directly determined by -counting in each brain
slices.
2.8. Statistical analysis
Results were expressed as means ± S.E.M. Statis-
tical significance was determined by one-way analy-
sis of variance (ANOVA) followed by the Bonferroni’s
multiple comparison test. Differences were considered
significant for p < 0.05.
3. Results
3.1. VIP is efﬁciently encapsulated into vesicles
VIP was entrapped in the glucose-bearing vesicles
(3.03 × 10−12 ± 1.05 × 10−13 mol (1.01 × 10−8 ±
3.51 × 10−10 g) per gram niosome, corresponding to
24.07 ± 0.83% of the initial VIP) and in the control
vesicles (3.28 × 10−12 ± 7.27 × 10−14 mol (1.09
× 10−8 ± 2.42 × 10−10 g) per gram niosome, corre-
sponding to 25.32± 0.56% of the initial VIP). Control
vesicles loaded with VIP had a z-average mean diame-
ter of 214 nm, while glucose vesicles loaded with VIP
had a z-average mean diameter of 220 nm.
3.2. VIP entrapped in vesicles reaches the brain,
and targeting with glucose improves the uptake
No unexpected mortality of any animals occurred
after administration of the VIP formulations used in
the present study. As a result, vesicles were considered
to be safe at the dosing schedule used. Radioactivity
could be detected in the brain following the adminis-
tration of glucose-bearing vesicles, indicating a pas-
sage of their content from the blood compartment into
the brain parenchyma (Fig. 1). Brain radioactivity up-
take was independent of the presence or not of BSA
in the formulation: brain radioactivity level was 1.892
± 329 cpm/g after administration of VIP vesicles pre-
pared without BSA, not significantly different to 1.544
± 325 cpm/g observed after administration of the vesi-
cles prepared with this additive. The blood radioactivity
Fig. 1. Radioactivity uptake in the blood (left columns) and in
the brain (right columns) after systemic administration of glucose-
bearing vesicles encapsulating VIP with or without BSA (four ani-
mals per formulation).
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Fig. 2. Time-related radioactivity in brain (A) and blood (B) after
systemic administrations of VIP encapsulated in glucose-bearing
vesicles (a, d, g); encapsulated in control vesicles (b, e, h) and in
solution (c, f, i) (four animals per formulation). Significant differ-
ence: a vs. (b, g), c vs. (b, f, i), d vs. (e, f). Blood radioactivity levels
are not significantly different.
levels obtained after administration of these two for-
mulations were also very similar (respectively 3.879±
883 cpm/g and 3.966 ± 876 cpm/g with and without
BSA) (Fig. 1).
Brain and blood radioactivity was then measured
at various time points after administration of VIP
in different formulations (in solution, entrapped in
glucose-bearing vesicles or in control vesicles, both of
them prepared with BSA), as shown in Fig. 2. For vesi-
cles prepared with and without glucose, the maximum
brain uptake was reached 15 min post-administration
(Fig. 2A). The glucose modified vesicles significantly
increased brain radioactivity levels by comparison
with control vesicles (by about 86% and 58% re-
spectively 5 min and 15 min after treatment). With
glucose-bearing vesicles, the brain radioactivity lev-
els measured 15 min after the last intravenous injection
represented 0.26% ± 0.04% of the total radioactivity
administered. After 30 min of administration, a reduced
and similar residual level of radioactivity was found
in the brain, as well in control (without glucose) or
glucose-bearing vesicles. This might be due to a clear-
ance (cerebrospinal fluid draining) or a degradation
process limiting the amount of peptide inside the brain.
Regardless of the formulations, the blood radioac-
tivity remained constant at each time point examined
(Fig. 2B).
3.3. Intact VIP is found in brain after
administration in vesicles with BSA
HPLC analysis performed on the brain extracts
showed no peak corresponding to intact VIP after
administration of glucose-bearing vesicles entrapping
VIP without BSA (Fig. 3A). In contrast, a peak of
radioactivity corresponding to intact VIP could be
observed after administration of glucose-bearing vesi-
cles entrapping VIP with BSA (Fig. 3B). Analysis also
showed one peak corresponding to intact VIP as well
after administration of vesicles without glucose but
with BSA (Fig. 3C). The presence of BSA could de-
crease the interaction of VIP to lipids in the niosome
membrane, thus allowing VIP to be released out of the
vesicle.
In our HPLC experimental conditions, free radioio-
dine should elute very quickly, after few minutes of
elution. Such early radioactive peak is not observed
in experiments corresponding to glucose-bearing nio-
somes, indicating that radiolysis of the 125I-VIP does
not occur in these experiments, at least for the fraction
of radioligand that reached the brain.
No peak could be detected after administration of
free VIP (Fig. 3D).
3.4. Glucose-bearing vesicles target speciﬁc
cerebral regions
After administration of glucose-bearing vesicles,
the radioactivity in the brain accumulated specifically
in the posterior and the anterior parts of the brain
(Fig. 4A). Counts for the posterior and the anterior sec-
tors were respectively about two times and 1.5 times
those read for the median sector or the cerebellum.
By contrast, no such pattern was observed following
administration of VIP in control vesicles (Fig. 4B) or
in solution (Fig. 4C). The distribution of radioactivity
throughout the whole brain was homogenous.
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Fig. 3. Reversed-phase HPLC elution profiles of brain extracts obtained after intravenous administrations of VIP encapsulated in glucose-vesicles
without BSA (A) or with BSA (B), VIP encapsulated in vesicles without glucose but with BSA (C) or as a solution (D), using 125I-VIP as a tracer
(three animals per formulation). 125I-VIP was evaluated by -counting. Intact VIP eluted in fractions 13–15. For more details see materials and
methods.
4. Discussion
In a previous work (Dufes et al., 2000), we have re-
ported the design and the characterization of glucose-
bearing niosomes, as well as their ability to bind to
concanavalin A. The present study is an in vivo evalu-
ation of these vesicles as a potential system to deliver
the neuropeptide VIP into the brain.
There are three key findings of this study. First, we
demonstrated that niosomes seem to be able to rapidly
deliver intact VIP into brain provided that this neu-
ropeptide is encapsulated in presence of BSA. Sec-
ondly, the presence of glucose ligands on the vesicles
seems to improve this uptake, at least for the two first
time points studied. Finally, only the administration of
glucose-bearing vesicles induced a characteristic brain
distribution of radioactivity, among which is intact
VIP.
An important difficulty in CNS pharmacology is to
elaborate tools able to overcome the limited penetration
of peptidic drugs through the BBB. Our results suggest
that VIP seems to be present as an intact molecule in
cerebral extracts and in brain slices after systemic ad-
ministration of niosomes encapsulating VIP. Although
the mechanisms underlying stability and interaction of
VIP in niosomes were not elucidated in this study,
they might be related, in part, to the encapsulation
of VIP in the vesicles’ aqueous core. Such insertion
might protect the peptide from degradation and might
shift peptide conformation from random coil to he-
lix, the optimal structure for VIP receptor interactions
(Bodanszky et al., 1974; Robinson et al., 1982). To this
end, Gao et al. (1994), Suzuki et al. (1996), Se´journe´
et al. (1997), Gololobov et al. (1998) and ¨Onyu¨ksel et
al. (1999) showed that liposomal VIP was resistant to
proteolytic cleavage, as a result of the impermeability
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Fig. 4. Brain radioactivity distribution profiles after intravenous ad-
ministration of VIP encapsulated in glucose-vesicles (A) or in vesi-
cles without glucose (B), or free VIP (C), using 125I-VIP as a tracer
(three animals per formulation). Radioactivity was evaluated by -
counting of the 2.5-mm thick brain slices. Arrows on the mouse brain
schema denote the approximate spacing of the brain slices. For more
details, see Section 2. In A, significant differences in radioactivity
levels were found between Sections 1–4. Differences in B and C are
not significant.
of the vesicular bilayer to trypsin. In view of the abil-
ity of liposome constituents to interact with VIP, it is
therefore hypothesized that VIP is “locked in” the vesi-
cles by binding to lipids in the niosome membranes
(Gololobov et al., 1998). The presence of BSA could
decrease this interaction, thus allowing VIP to be re-
leased out of the vesicle.
When considering the uptake of radioactivity into
the brain, the glucose modified vesicles led to signifi-
cantly increased brain radioactivity levels compared to
control vesicles (Fig. 2A). VIP degradation products,
like other low molecular weight molecules, may enter
cells by passive non-specific diffusion. High molecular
weight carriers could eventually:
• be taken up via endocytosis, a comparatively slower
but potentially more specific process, if their size
allows this passage;
• or bind the BBB and release their content through
the luminal membrane of the endothelial cells.
The glucose-targeted vesicles increased the brain
uptake when compared to non-targeted vesicles.
The importance of carbohydrate-mediated recogni-
tion by specific cells has already been demonstrated.
Umezawa and Eto (1988) reported that liposomes bear-
ing aminophenyl mannoside were efficiently taken up
into the mouse brain, suggesting that mannose could
be recognized by the cells of the BBB. The BBB cells
are known to express high levels of the glucose trans-
porter GLUT1 (Dick et al., 1984). Therefore, an active
targeting based on GLUT1 ligands could be a useful
strategy for drug delivery in the brain. To our knowl-
edge, our study is the first demonstration that VIP ad-
ministered intravenously in targeted systems such as
glucose-bearing niosomes is efficiently delivered to the
brain.
Finally, we examined whether the different lev-
els of brain radioactivity obtained after VIP admin-
istration through targeted or control vesicles display
specific distributions. While control vesicles admin-
istration leads to an homogeneous distribution of ra-
dioactivity throughout the whole brain, the addition of
glucose on the surface of the vesicles clearly modulated
brain distribution of VIP derived radioactivity, among
which was intact VIP (Fig. 4A). Since the glucose trans-
porter GLUT1 present on the BBB cells may recognize
-d-glucose ligands of niosome surface, improvement
may therefore be linked to a relatively higher glucose
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transporter concentration in some brain regions. This
idea is supported by previous studies showing the pres-
ence of GLUT1 in considerable amounts throughout
the brain, but with some regional variations (Brant et
al., 1993; Rayner et al., 1994; Dobrogowska and
Vorbrodt, 1999). Western blot studies revealed a rela-
tively higher density in the posterior region of the brain
such as the cerebellum (Brant et al., 1993; Rayner et al.,
1994), whereas immunohistochemistry approaches in-
dicated that GLUT1 was present in equal high amounts
in the anterior cortex, the hippocampus and the cere-
bellum (Dobrogowska and Vorbrodt, 1999; Choeiri et
al., 2002).
Moderate to low GLUT1 levels have been reported
in the same studies (Dobrogowska and Vorbrodt, 1999;
Choeiri et al., 2002) for the olfactory bulb, the stria-
tum, the thalamus, the hypothalamus, the brainstem
and the medulla. Interestingly, we observed high levels
of radioactivity in Section 4 (including frontal, orbital
and motor cortical areas) and Section 2 (including ret-
rosplenial, visual and auditory cortices, hippocampus
and midbrain). Sections with lower levels of radioactiv-
ity include brain regions containing lower densities of
GLUT1 (striatum, thalamus, hypothalamus for Section
3; pons and medulla for Section 1). It should be noted in
addition that orbital, retrosplenial, visual and auditory
cortices exhibit significantly higher levels of glucose
utilization (LCGU indices) than any other cortical area
in the normal rat (Zilles and Wree, 1995). Together,
high density of GLUT1 receptors and important rate
of metabolic activity in these cortical areas could be
responsible of the high VIP uptake observed in the an-
terior and posterior parts of the brain (Dobrogowska
and Vorbrodt, 1999).
In conclusion, the present study demonstrated that
the administration of systemic glucose-bearing vesi-
cles encapsulating VIP could deliver intact VIP to
specific brain areas. Therefore, glucose-bearing vesi-
cles represent a novel tool to deliver drugs across the
BBB.
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